You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 1
  • 09.01 Armoring anti-HER2 CAR-T cells with C-C-motive receptor 8 (CCR8) and a dominant negative TGF-b receptor (DNR) to enable efficacy in solid tumor models

Article info

Article menu

Download PDFPDF

Oral Presentations
Plenary session 9: young researcher session
09.01 Armoring anti-HER2 CAR-T cells with C-C-motive receptor 8 (CCR8) and a dominant negative TGF-b receptor (DNR) to enable efficacy in solid tumor models
Free

Authors

  • TJ Strzalkowski Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Lindwurmstrasse 2a, 80337 Munich, Germany, Munich, Germany PubMed articlesGoogle scholar articles
  • BL Cadilha Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Lindwurmstrasse 2a, 80337 Munich, Germany, Munich, Germany PubMed articlesGoogle scholar articles
  • I Dalloul Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Lindwurmstrasse 2a, 80337 Munich, Germany, Munich, Germany PubMed articlesGoogle scholar articles
  • K Manske Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Lindwurmstrasse 2a, 80337 Munich, Germany, Munich, Germany PubMed articlesGoogle scholar articles
  • S Endres Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Lindwurmstrasse 2a, 80337 Munich, Germany, Munich, Germany German Cancer Consortium (DKTK), Partner Site Munich, Pettenkoferstrasse 8a, 80336 Munich, Germany, Munich, Germany Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany, Neuherberg, Germany PubMed articlesGoogle scholar articles
  • S Kobold Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University (LMU) of Munich, Lindwurmstrasse 2a, 80337 Munich, Germany, Munich, Germany German Cancer Consortium (DKTK), Partner Site Munich, Pettenkoferstrasse 8a, 80336 Munich, Germany, Munich, Germany Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany, Neuherberg, Germany PubMed articlesGoogle scholar articles

Citation

Strzalkowski T, Cadilha B, Dalloul I, et al
09.01 Armoring anti-HER2 CAR-T cells with C-C-motive receptor 8 (CCR8) and a dominant negative TGF-b receptor (DNR) to enable efficacy in solid tumor models
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-ITOC9.6

Publication history

  • First published September 21, 2022.
Online issue publication 
September 21, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.